Why MannKind Corporation Dipped 4.8% in November
In response to the company reporting worse-than-expected third-quarter results, shares of MannKind (NASDAQ: MNKD), a commercial-stage biotech focused on inhaled insulin, fell about 5% in November, according to data from S&P Global Market Intelligence.
Here's a quick review of the headline numbers from the quarter:
Given the bummer news, it isn't surprising to see that shares took a step back in November.
Source: Fool.com
